Related Experiment Video

Updated: Jun 30, 2026

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

Therapeutic options in hypertrophic cardiomyopathy: a pediatric perspective

Edward K Rhee1, John J Nigro, Stephen G Pophal

  • 1Scott & Laura Eller Congenital Heart Center, St. Joseph's Hospital and Medical Center, 500 West Thomas Road, Suite 500, Phoenix, AZ 85013, USA. Edward.Rhee@chw.edu

Current Treatment Options in Cardiovascular Medicine
|September 26, 2008
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a common genetic heart condition in young people. Despite identical genetic mutations, clinical outcomes in HCM patients vary significantly, complicating diagnosis and treatment.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most common genetic heart muscle disease in children and young adults.
  • HCM presents with a wide spectrum of clinical phenotypes, ranging from asymptomatic hypertrophy to severe heart failure and sudden cardiac death.
  • The genetic basis of HCM is complex, with significant variability in clinical presentation even among individuals with the same mutation.

Purpose of the Study:

  • To highlight the challenges in predicting clinical outcomes in hypertrophic cardiomyopathy (HCM) despite advances in understanding its molecular etiology.
  • To emphasize the wide variability of clinical phenotypes observed in HCM patients, irrespective of specific genetic defects.
  • To outline the current diagnostic and therapeutic approaches for individuals with HCM.

Main Methods:

  • Review of current understanding of hypertrophic cardiomyopathy (HCM) genetics and clinical manifestations.
  • Analysis of the discordance between genetic mutations and clinical phenotypes in HCM.
  • Description of diagnostic methods including cardiac imaging and risk stratification for sudden death.
  • Overview of treatment strategies for symptomatic left ventricular outflow tract obstruction (LVOTO) in HCM.

Main Results:

  • Identical genetic mutations in hypertrophic cardiomyopathy (HCM) do not consistently predict clinical outcomes or disease severity.
  • Significant phenotypic heterogeneity exists within families affected by HCM, underscoring the complexity of genotype-phenotype correlations.
  • Current evaluation involves cardiac imaging, sudden death risk assessment, and management of obstructive symptoms.

Conclusions:

  • Predicting the clinical course of hypertrophic cardiomyopathy (HCM) based solely on genetic defects remains challenging due to significant phenotypic variability.
  • Comprehensive evaluation including imaging and risk stratification is crucial for managing HCM patients.
  • Further research is needed to elucidate factors influencing the diverse clinical presentations of HCM.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.